Published by Josh White on 28th March 2024
(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA).
URL: http://www.digitallook.com/dl/news/story/34188347/...